Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132217) titled 'A Single-Arm, Single-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined with Paclitaxel and Cisplatin/Carboplatin in Patients with Persistent Cervical Cancer After Concurrent Chemoradiotherapy' on Sept. 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Henan Cancer Hospital

Condition: Persistent cervical cancer after concurrent chemoradiotherapy

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-09-15

Target Sample Size: Experimental group:29;

Countries of Recruitment: China

To k...